Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.71 |
| ▸ | FYN | P06241 | 13/20 | 0.67 |
| ▸ | PIM1 | P11309 | 4/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033272 | 0.90 | FYN (0.65) | MKNK1FYNPIM1KCNH2 | |
| SCHEMBL2947994 | 0.90 | FYN (0.65) | MKNK1FYNPIM1KCNH2 | |
| SCHEMBL1055637 | 0.89 | FYN (0.78) | MKNK1FYNPIM1KCNH2 | |
| SCHEMBL1053592 | 0.86 | MKNK1 (0.78) | MKNK1FYNPIM1KCNH2 | |
| SCHEMBL1054456 | 0.85 | MKNK1 (0.76) | MKNK1FYNPIM1KCNH2 | |
| SCHEMBL3031883 | 0.83 | MKNK1 (1.00) | MKNK1FYNPIM1KCNH2 | |
| SCHEMBL3041980 | 0.82 | MKNK1 (0.97) | MKNK1FYNPIM1KCNH2 | |
| SCHEMBL1055831 | 0.82 | MKNK1 (0.71) | MKNK1FYNPIM1KCNH2 | |
| SCHEMBL15254504 | 0.82 | MKNK1 (0.71) | MKNK1FYNPIM1KCNH2 | |
| SCHEMBL16010358 | 0.81 | FYN (0.64) | MKNK1FYNPIM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | claimed |
| EP-2063962-A2 | IRAK MODULATORS FOR TREATING AN INFLAMMATORY CONDITION, CELL PROLIFERATIVE DISORDER, IMMUNE DISORDER | Biogen Idec MA Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2008030579-A2 | IRAK MODULATORS FOR TREATING AN INFLAMMATORY CONDITION, CELL PROLIFERATIVE DISORDER, IMMUNE DISORDER | BIOGEN IDEC MA INC. (US) | 2008-03-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | IRAK1, IRAK2, IRAK3 | MKNK1 105/4885FYN 666/4885PIM1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.